TARO-DESVENLAFAXINE TABLET (EXTENDED-RELEASE)
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
19-10-2022
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
Inapatikana kutoka:
TARO PHARMACEUTICALS INC
ATC kanuni:
N06AX23
INN (Jina la Kimataifa):
DESVENLAFAXINE
Kipimo:
100MG
Dawa fomu:
TABLET (EXTENDED-RELEASE)
Tungo:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
15G/50G
Dawa ya aina:
Prescription
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0152509002; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2022-10-20
Tabia za bidhaa
PRODUCT MONOGRAPH
PR TARO-DESVENLAFAXINE
desvenlafaxine extended-release tablets
50 mg and 100 mg desvenlafaxine (as desvenlafaxine succinate
monohydrate
)
Antidepressant
Taro Pharmaceuticals Inc.
Date of Revision:
130 East Drive
OCT 19, 2022
Brampton, Ontario
L6T 1C1
Submission Control No.: 264187
_________________________________________________________________________________________
_Taro-Desvenlafaxine (desvenlafaxine succinate monohydrate) Product
Monograph _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFOR
M
ATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
............................................................................................................................11
DRUG INTERACTIONS
.............................................................................................................................21
DOSAGE AND ADMINISTRATION
.........................................................................................................24
OVERDOSAGE
...........................................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................28
STORAGE AND STABILITY
....................................................................................................................31
SPECIAL HANDLING INSTRUCTIONS
.
Soma hati kamili
